Fecal Microbiota Transplantation Clinical Trial
— RIT;TETOfficial title:
Methodology and Clinical Value of Retrograde Imaging Technique in Intestinal Obstructive Diseases Mediated by Colonic Transendoscopic Enteral Tubing
The etiology of bowel obstruction is usually diagnosed by imaging techniques such as MSCTE,MRE, et al, which have some disadvantages. For example, in order to obtain better image quality, MSCTE(Multi-slices spiral computed tomography enterography) and MRE( Magnetic resonance enterography)require patients to take a large amount of intestinal contrast solution orally, while for patients with intestinal obstruction, which may further aggravate the disease. Our study team had confirmed the mid-gut TET could serve as the delivery way of contrast solution for MRE bowel preparation with better accuracy of lesion detection and lower reduction of pain in CD(Crohn's Disease) patients. In this study, contrast solution will be delivered by colonic TET placed by lower GI-endoscopy, then we will evaluate the methodology and clinical value of this kind retrograde imaging technique in patients with intestinal obstructive diseases.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | June 1, 2023 |
Est. primary completion date | February 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Symptoms of intestinal obstruction such as abdominal pain, abdominal distension, nausea, vomiting, cessation of anal exhaust and defecation; - Abdominal X-ray or plain CT showed signs of intestinal obstruction; - Participants suspected with intestinal stricture according to the recent lower GI endoscopy; - Voluntarily sign written informed consent. Exclusion Criteria: - Signs of peritonitis, perforation or massive hemorrhage of digestive tract; - Accompanied with severe heart, brain, lung and kidney dysfunction, unable to take lower GI endoscopy; - Allergic to laxatives or iodine contrast agents; - Pregnant women; - Confirmed or suspected claustrophobia; - Inability to understand or provide informed consent |
Country | Name | City | State |
---|---|---|---|
China | Medical Center for Digestive Diseases, Second Affiliated Hospital of Nanjing Medical University | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
The Second Hospital of Nanjing Medical University | SIR RUN RUN hospital of Nanjing Medical University, The First Affiliated Hospital of Guangdong Pharmaceutical University, Wuxi No. 2 People's Hospital |
China,
Catena F, De Simone B, Coccolini F, Di Saverio S, Sartelli M, Ansaloni L. Bowel obstruction: a narrative review for all physicians. World J Emerg Surg. 2019 Apr 29;14:20. doi: 10.1186/s13017-019-0240-7. eCollection 2019. Review. — View Citation
Dai M, Zhang T, Li Q, Cui B, Xiang L, Ding X, Rong R, Bai J, Zhu J, Zhang F. The bowel preparation for magnetic resonance enterography in patients with Crohn's disease: study protocol for a randomized controlled trial. Trials. 2019 Jan 3;20(1):1. doi: 10.1186/s13063-018-3101-x. — View Citation
Masselli G, Gualdi G. CT and MR enterography in evaluating small bowel diseases: when to use which modality? Abdom Imaging. 2013 Apr;38(2):249-59. doi: 10.1007/s00261-012-9961-8. Review. — View Citation
Peng Z, Xiang J, He Z, Zhang T, Xu L, Cui B, Li P, Huang G, Ji G, Nie Y, Wu K, Fan D, Zhang F. Colonic transendoscopic enteral tubing: A novel way of transplanting fecal microbiota. Endosc Int Open. 2016 Jun;4(6):E610-3. doi: 10.1055/s-0042-105205. Epub 2016 Apr 28. — View Citation
Rami Reddy SR, Cappell MS. A Systematic Review of the Clinical Presentation, Diagnosis, and Treatment of Small Bowel Obstruction. Curr Gastroenterol Rep. 2017 Jun;19(6):28. doi: 10.1007/s11894-017-0566-9. Review. — View Citation
Sheedy SP, Kolbe AB, Fletcher JG, Fidler JL. Computed Tomography Enterography. Radiol Clin North Am. 2018 Sep;56(5):649-670. doi: 10.1016/j.rcl.2018.04.002. Epub 2018 Jul 11. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The diagnostic self-confidence score | Image parameters of the lesion( i e. Location,Nature, Severity, Appearance, Fistula) will be recorded by the reader.
The diagnostic self-confidence for each image parameter will be determined using a continuous five-grade scoring system from 1 to 5(1 = worst, 2=worsen, 3=normal, 4= better,5 = best). For example: The doctor's diagnostic self-confidence for Location is worsen ,then the diagnostic self-confidence score will be recorded as 2? |
immediately after CT/X-ray fluoroscopy detection,no more than 24hours. | |
Primary | Evaluation of comprehensive diagnostic efficiency | comprehensive diagnostic efficiency=(Location+Nature+Appearance+Fistula+Proximal lesion filled by contrast fluid). Each positive parameter will be recorded as mark 1, negative mark 0. Each participant will get up to 5 score.
For example: for some one participant ,if the doctor could determine the location and nature of the lesion, however,appearance, fistula and proximal lesion filled by contrast fluid could not be determined, then ,the score of comprehensive diagnostic efficiency equals 2. |
immediately after CT/X-ray fluoroscopy detection,no more than 24hours. | |
Secondary | Adverse reaction | Adverse reaction( abdominal pain, abdominal distention, nausea, vomiting) will be recorded and graded by score 1 to 5 according to the severity of each symptom. | during the process, and no more than 24hours after CT/X-ray fluoroscopy detection | |
Secondary | Tolerance | Tolerance will be evaluated by questionnaire investigation?1--Severely intolerable;2--Moderately intolerable;3--Slightly intolerable;4--Tolerable? | during the process, and no more than 24hours after CT/X-ray fluoroscopy detection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04436874 -
Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease
|
N/A | |
Recruiting |
NCT03325855 -
Fecal Microbiota Transplant National Registry
|
||
Completed |
NCT06162702 -
Clinical Study of Fecal Microbiota Transplantation in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)
|
N/A | |
Active, not recruiting |
NCT05607745 -
Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study
|
N/A | |
Completed |
NCT05121285 -
Distribution of FMT After Delivery by · Lower GI Endoscopy vs Enema With and Without Positioning of the Patient
|
N/A | |
Active, not recruiting |
NCT05917379 -
The Safety and Efficacy of FMT in Patients With CID
|
Phase 1/Phase 2 | |
Recruiting |
NCT02318147 -
Fecal Microbiota Transplantation for Pancreatitis With Infectious Complications(FMTPIC)
|
Phase 1 | |
Completed |
NCT02318134 -
Fecal Microbiota Transplantation for Pancreatitis
|
Phase 2 | |
Completed |
NCT05035784 -
RCE With FMT in the Treatment of Childhood Constipation
|
N/A | |
Active, not recruiting |
NCT04173208 -
Main Trial of the Cesarean Section and Intestinal Flora of the Newborn Study
|
N/A | |
Terminated |
NCT04577729 -
The IRMI-FMT Trial
|
N/A | |
Not yet recruiting |
NCT02435160 -
The Study of Efficacy and Mechanism in Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT04837313 -
Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Parkinson's Disease With Constipation
|
N/A | |
Recruiting |
NCT04861649 -
Metabonomics of COPD and Transplanting of Faecal Bacteria in the Treatment of Its Malnutrition
|
N/A | |
Withdrawn |
NCT04078581 -
Profiling Fecal Samples for Selection of Donors of Feces
|
N/A | |
Recruiting |
NCT05821010 -
Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05273255 -
Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy
|
N/A | |
Recruiting |
NCT04285424 -
FMT for Steroid Resistant Gut Acute GVHD
|
Early Phase 1 | |
Withdrawn |
NCT03527056 -
Pilot Study Using Oral Capsule FMT to Decolonize GI CRE
|
Early Phase 1 | |
Recruiting |
NCT03016780 -
Fecal Microbiota Transplantation for Ulcerative Colitis
|
Phase 1/Phase 2 |